Grace Therapeutics (GRCE) Receivables - Other (2020 - 2026)

Grace Therapeutics has disclosed Receivables - Other across 7 years of filings, most recently posting $20000.0 for Q2 2026.

• In Q2 2026, Receivables - Other changed 0.0% year-over-year to $20000.0; the TTM figure through Jun 2026 stood at $20000.0 (changed 0.0% YoY), while the FY2026 annual figure was $20000.0, down 84.13% from the prior year.
• Receivables - Other came in at $20000.0 for Q2 2026 at Grace Therapeutics, roughly flat from $20000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $722000.0 in Q1 2024 to a low of $11000.0 in Q1 2022.
• Average Receivables - Other over 5 years is $137000.0, with a median of $50000.0 recorded in 2023.
• Year-over-year, Receivables - Other jumped 1288.46% in 2024 and slumped 95.18% in 2025.
• Over 5 years, Receivables - Other stood at $11000.0 in 2022, then jumped by 1390.91% to $164000.0 in 2023, then jumped by 83.54% to $301000.0 in 2024, then slumped by 93.36% to $20000.0 in 2025, then changed by 0.0% to $20000.0 in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $20000.0 in Q2 2026, $20000.0 in Q1 2026, and $20000.0 in Q4 2025.